
## **ESSENTIALS IN OPHTHALMOLOGY** G.K.KRIEGLSTEIN · R.N.WEINREB Series Editors





Surgery

Immunological

Disorders





Retina



Oculoplastics and Orbit

tics Pediatric Ophthaln Neuro-



Ophthalmology, Neuro-Ophthalmology, Genetics Cornea and External Eye Disease

# Glaucoma

Edited by F.GREHN R.STAMPER





#### Essentials in Ophthalmology

#### Glaucoma

F.Grehn R.Stamper Editors

#### Essentials in Ophthalmology

G.K.Krieglstein R.N.Weinreb Series Editors Glaucoma

**Cataract and Refractive Surgery** 

**Uveitis and Immunological Disorders** 

Vitreo-retinal Surgery

**Medical Retina** 

**Oculoplastics and Orbit** 

Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics

**Cornea and External Eye Disease** 

Editors Franz Grehn Robert Stamper

## Glaucoma

With 68 Figures, Mostly in Colour and 18 Tables



#### Series Editors

#### Günter K. Krieglstein, MD

Professor and Chairman Department of Ophthalmology University of Cologne Kerpener Straße 62 50924 Cologne Germany

#### Robert N. Weinreb, MD

Professor and Director Hamilton Glaucoma Center Department of Ophthalmology - 0946 University of California at San Diego 9500 Gilman Drive La Jolla, CA 92093-0946 USA

#### Volume Editors

#### Franz Grehn, MD

Professor and Chairman Department of Ophthalmology University of Wuerzburg Josef-Schneider-Straße 11 97080 Wuerzburg Germany

#### **Robert Stamper, MD**

Director of Glaucoma Service Department of Ophthalmology USCF 10 Kirkham Street, Rm K301 San Francisco, CA 94143 USA

ISBN-10 3-540-26220-2 Springer Berlin Heidelberg NewYork

ISBN-13 978-3-540-26220-6 Springer Berlin Heidelberg NewYork ISSN 1612-3212

#### Library of Congress Control Number: 2004042952

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer is a part of Springer Science + Business Media

springer.com

© Springer-Verlag Berlin Heidelberg 2006 Printed in Germany The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Editor: Marion Philipp, Heidelberg, Germany Desk Editor: Martina Himberger, Heidelberg, Germany Production: LE-TeX Jelonek, Schmidt & Vöckler GbR, Leipzig, Germany Cover Design: Erich Kirchner, Heidelberg, Germany

Printed on acid-free paper 24/3100Di 543210

## Foreword

The series *Essentials in Ophthalmology* was initiated two years ago to expedite the timely transfer of new information in vision science and evidence-based medicine into clinical practice. We thought that this prospicient idea would be moved and guided by a resolute commitment to excellence. It is reasonable to now update our readers with what has been achieved.

The immediate goal was to transfer information through a high quality quarterly publication in which ophthalmology would be represented by eight subspecialties. In this regard, each issue has had a subspecialty theme and has been overseen by two internationally recognized volume editors, who in turn have invited a bevy of experts to discuss clinically relevant and appropriate topics. Summaries of clinically relevant information have been provided throughout each chapter.

Each subspecialty area now has been covered once, and the response to the first eight volumes in the series has been enthusiastically positive. With the start of the second cycle of subspecialty coverage, the dissemination of practical information will be continued as we learn more about the emerging advances in various ophthalmic subspecialties that can be applied to obtain the best possible care of our patients. Moreover, we will continue to highlight clinically relevant information and maintain our commitment to excellence.

G.K.Krieglstein R.N.Weinreb Series Editors

## Preface

This second volume in the series *Essentials of Ophthalmology*, as in the first, seeks to bring the ophthalmic practitioner up to date on the important new advances or changes in glaucoma diagnosis and management that has occurred in the last 10 years. The last decade has seen significant changes in our understanding of the pathophysiology of some glaucomas, both in our diagnostic approaches and in our management. Toward the goal of providing the most up-to-date information in a readable fashion, we have asked some of the world's experts to discuss areas to which they have contributed in a way that will be useful for the practicing doctor.

For example, Dr. Johnstone, one pioneer in the study of trabecular meshwork, explains his new theories of how aqueous gets through the meshwork and Schlemm's canal. He proposes that the trabecular drainage system is not just a passive screen as has been conceived for the past century but a much more dynamic system than has been heretofore acknowledged.

Electrophysiology has improved both our understanding of the processes of glaucoma damage but has also provided new diagnostic tools. Thanks to the completion of several randomized controlled trials, we are now able to actually calculate the risk of developing glaucoma in a patient who is a glaucoma suspect. Dr. Mansberger explains this new development. Our understanding of the complicated issue of what factors drive our patients to follow our prescriptions or not has been given a boost by several studies in recent years. Dr. Schwartz describes some of the advances in our understanding of patient adherence and persistence.

Health economics, rarely discussed before in this kind of ophthalmic venue, has become more important as healthcare groups, health insurers and governments grapple with the problems of providing ophthalmic care with resources that are stressed by ever-increasing demands and options. This issue is addressed by Dr. Tuulonen, as is the problem of glaucoma in the developing world which, as difficult as it may be with firstrate resources, becomes even more daunting when the resources are severely limited.

Drs. Kaufman and Gabelt give us a look at the future of medical treatment. The use of new imaging techniques has given us new insights into the pathophysiology of filtering blebs.

Dr. Freedman updates our concepts of tubeshunt procedures and offers some practical advice on how to improve results. Many of the mechanisms discussed and illustrated in this volume have not appeared in textbook format before. We hope that all the topics and authors we have selected are helpful in improving the understanding of the many faces of glaucoma and will ultimately contribute to reduced visual loss and better care for our patients.

Franz Grehn Robert L. Stamper

## Contents

#### **Basics and Diagnosis**

#### Chapter 1

#### A New Model Describes an Aqueous Outflow Pump and Explores Causes of Pump Failure in Glaucoma

#### Murray A. Johnstone

| 1.1   | Introduction 3                 |
|-------|--------------------------------|
| 1.1.1 | Overview 3                     |
| 1.1.2 | The Trabecular Meshwork        |
|       | Is the Wall of a Vessel 4      |
| 1.1.3 | The Aqueous Outflow            |
|       | System Is Part of a Vascular   |
|       | Circulatory Loop 4             |
| 1.1.4 | Circulatory Loops              |
|       | Return Fluid to the Heart      |
|       | by Pumping Mechanisms 5        |
| 1.2   | Laboratory Evidence            |
|       | of a Mechanical Aqueous        |
|       | Outflow Pump 6                 |
| 1.2.1 | Anatomic Relationships That    |
|       | Permit Pulsatile Flow 6        |
| 1.2.2 | IOP Transients Move            |
|       | Trabecular Tissues to Power    |
|       | the Pump 7                     |
| 1.2.3 | IOP Decreases Cause            |
|       | Trabecular Tissue Recoil 8     |
| 1.2.4 | Trabecular Tissues Respond     |
|       | to IOP Transients              |
| 1.2.5 | Trabecular Tissues Move        |
|       | with the Ocular Pulse 8        |
| 1.3   | The Aqueous Valves 9           |
| 1.3.1 | Appearance and                 |
|       | Relationships                  |
| 1.3.2 | Valves in SC Carry Aqueous . 9 |
| 1.4.  | Trabecular Tissues and         |
|       | Aqueous Valves Are the         |
|       | Pump 12                        |
| 1.4.1 | Trabecular Tissues Distend     |
|       | and Recoil with IOP            |
|       | Changes 12                     |

| 1.4.2 | Trabecular Tissue Movement     |    |
|-------|--------------------------------|----|
|       | Moves Aqueous                  | 12 |
| 1.4.3 | IOP Transients Provide         |    |
|       | Energy to Power the Pump       | 12 |
| 1.5   | Clinical Evidence of a         |    |
|       | Mechanical Aqueous             |    |
|       | Outflow Pump                   | 12 |
| 1.5.1 | Clinical Evidence of Pulsatile |    |
|       | Aqueous Flow                   | 13 |
| 1.6   | Pump Regulation of             |    |
|       | Pressure and Flow: Short       |    |
|       | Term                           | 14 |
| 1.6.1 | Length-to-Tension              |    |
|       | Relationships Govern Stroke    |    |
|       | Volume                         | 14 |
| 1.6.2 | Clinical Evidence of Pump-     |    |
|       | Dependent Pressure             |    |
|       | Regulation                     | 15 |
| 1.7   | Pump Regulation                |    |
|       | of Pressure and Flow:          |    |
|       | Long Term                      | 16 |
| 1.7.1 | Trabecular Tissue              |    |
|       | Information Networks           | 16 |
| 1.7.2 | Trabecular Tissue Tethers      |    |
|       | and Signaling Mechanisms       | 17 |
| 1.7.3 | Endothelial Cells Regulate     |    |
|       | Trabecular Tissue              |    |
|       | Composition                    | 17 |
| 1.7.4 | Regulation of Trabecular       |    |
|       | Tissue Composition Is Pump     |    |
|       | Regulation                     | 18 |
| 1.8   | The Pump Fails to Control      |    |
|       | Pressure in Glaucoma           | 19 |
| 1.8.1 | Overview of the Failure        |    |
|       | Mechanism                      | 19 |
| 1.8.2 | Laboratory Evidence:           |    |
|       | Pump Failure Mechanisms        |    |
|       | in Living Eyes                 | 19 |
| 1.8.3 | Laboratory Evidence:           |    |
|       | Pump Failure Mechanisms        |    |
|       | in Enucleated Eves             | 22 |

#### X Contents

| 1.9   | Clinical Evidence of Pump    |
|-------|------------------------------|
|       | Failure Mechanisms           |
|       | in Glaucoma 28               |
| 1.9.1 | Pulsatile Aqueous Flow       |
|       | Decreases in Glaucoma        |
|       | Eyes 28                      |
| 1.9.2 | Pulsatile Aqueous Flow       |
|       | Stops As IOP Increases       |
|       | in Glaucoma Eyes 28          |
| 1.9.3 | Pulsatile Aqueous Flow       |
|       | Stops with Episcleral Venous |
|       | Pressure Increases 29        |
| 1.9.4 | Pilocarpine: Pulsatile       |
|       | Aqueous Flow Increases       |
|       | When SC Expands 29           |
| 1.9.5 | SC Blood Reflux:             |
|       | Measure of Trabecular        |
|       | Tissue Movement 29           |
| 1.10  | Conclusion 32                |
|       | References 32                |
|       |                              |

#### Chapter 2

#### Risk Calculators: Evidence-Based Care of Ocular Hypertension and Glaucoma Patients

Steven L. Mansberger and Emily L. Patterson

| 2.1   | Introduction                    |
|-------|---------------------------------|
| 2.2   | Evidence from Recent            |
|       | Randomized Clinical Trials . 36 |
| 2.2.1 | Preventing or Delaying          |
|       | Glaucoma: The Ocular            |
|       | Hypertension Treatment          |
|       | Study 37                        |
| 2.2.2 | Treating Newly Diagnosed        |
|       | Glaucoma: the Early             |
|       | Manifest Glaucoma Trial         |
|       | and the Collaborative Initial   |
|       | Glaucoma Treatment Study 37     |
| 2.2.3 | Treating Moderate               |
|       | to Advanced Normal              |
|       | Tension Glaucoma: the           |
|       | Collaborative Normal-           |
|       | Tension Glaucoma Study 37       |
| 2.2.4 | Treating Uncontrolled           |
|       | Glaucoma: the Advanced          |
|       | Glaucoma Intervention           |
|       | Study 37                        |
| 2.2.5 | Integrating Information         |
|       | from Studies 38                 |

| 2.3   | How Do Clinicians Use This<br>Important Information |
|-------|---|
|       | to Take Care of Patients? 38                        |
| 2.4   | Implementing Information                            |
|       | from Clinical Studies into                          |
|       | Clinical Care of Patients 40                        |
| 2.4.1 | A Current Risk Calculator:                          |
|       | The Devers Ocular                                   |
|       | Hypertension to Glaucoma                            |
|       | Risk Calculator 40                                  |
| 2.4.2 | Benefits to Eye Care                                |
|       | Providers 40  |
| 2.4.3 | Benefits to Patients 41                             |
| 2.4.4 | Benefits to Society of a Risk                       |
|       | Calculator 42                                       |
| 2.4.5 | Disadvantages of Risk                               |
|       | Calculators 42                                      |
| 2.4.6 | Future Risk Calculators 43                          |
| 2.4.7 | Conclusion 44                                       |
|       | References 44                                       |

#### Chapter 3

#### **Dynamic Contour Tonometry**

Evelin Schneider, Hartmut E. Kanngiesser, Christoph Kniestedt

| 3.1   | Intraocular Pressure       | 47 |
|-------|----------------------------|----|
| 3.1.1 | IOP Measurement in         |    |
|       | Glaucoma Diagnosis         | 47 |
| 3.1.2 | Principles and Problems of |    |
|       | IOP Measurement Methods    | 48 |
| 3.1.3 | Comparison of Common       |    |
|       | Tonometers                 | 49 |
| 3.2   | Dynamic Contour            |    |
|       | Tonometry                  | 50 |
| 3.2.1 | Physical Methodology       | 50 |
| 3.2.2 | Measurement Procedure      | 51 |
| 3.2.3 | Absolute and Relative      |    |
|       | Accuracy                   | 53 |
| 3.3   | Clinical Application       |    |
|       | of Dynamic Contour         |    |
|       | Tonometry                  | 56 |
| 3.3.1 | Dynamic Contour            |    |
|       | Tonometry or Applanation   |    |
|       | Tonometry with Correction  |    |
|       | Factor?                    |    |
| 3.3.2 | DCT in LASIK Eyes          | 56 |
| 3.3.3 | DCT in Clinical Practice:  |    |
|       | Experiences, Advantages,   |    |
|       | and Disadvantages          |    |
|       | References                 | 61 |

Chapter 4

#### Effect of Corneal Thickness on Applanation Tonometry, Pneumotonometry, and Tonopen Measurements

Lutz E. Pillunat, Markus Kohlhaas, Andreas G. Boehm, Eberhard Spoerl

| 4.1 | Influencing Factors in      |    |
|-----|-----------------------------|----|
|     | Applanation Tonometry       | 65 |
| 4.2 | Approach to a Clinical      |    |
|     | Study                       | 65 |
| 4.3 | Results of a Clinical Study | 67 |
| 4.4 | Results of a Clinical Study |    |
|     | Pitfalls and Solutions for  |    |
|     | Tonometric Measurements     | 69 |
| 4.5 | Conclusion                  | 70 |
|     | References                  | 71 |

#### Chapter 5 Electrophysiology in the Diagnosis of Glaucoma

Thomas Meigen and Michael Bach

| 5.1   | Introduction 73             |
|-------|-----------------------------|
| 5.1.1 | Glaucomatous Damage         |
|       | of Ganglion Cells 73        |
| 5.1.2 | The Importance of Early     |
|       | Detection of Glaucoma 74    |
| 5.1.3 | Electrophysiological        |
|       | Procedures                  |
|       | in Ophthalmology 75         |
| 5.2   | Early Detection of Glaucoma |
|       | Using PERG Recordings 76    |
| 5.2.1 | PERG Recordings 76          |
| 5.2.2 | Neural Origin of PERG       |
|       | Responses 77                |
| 5.2.3 | PERG Changes                |
|       | in Glaucoma 78              |
| 5.2.4 | The "Freiburg" PERG         |
|       | Paradigm 81                 |
| 5.3   | VEP Recordings              |
|       | in Glaucoma 83              |
| 5.3.1 | Conventional VEP            |
|       | Recordings in Glaucoma 83   |
| 5.3.2 | Multifocal VEP Recordings   |
|       | in Glaucoma 85              |
|       | References 86               |
|       |                             |

#### Chapter 6 Adherence and Persistence in Glaucoma

Gail F. Schwartz

| 6.1<br>6.2<br>6.3<br>6.4 | Introduction<br>Adherence<br>Persistence<br>Barriers to Adherence | . 92 |
|--------------------------|---|------|
| 0.4                      | and Persistence   | . 99 |
| 6.4.1                    | Patient Demographics  | 100  |
| 6.4.2                    | Behavioral Factors  | 100  |
| 6.4.3                    | Treatment Regimen   |      |
|                          | Characteristics   | 101  |
| 6.4.4                    | Situational Factors   | 101  |
| 6.4.5                    | Health Care System Issues   | 101  |
| 6.5                      | Improving Adherence   |      |
|                          | and Persistence   | 101  |
| 6.5.1                    | Improve Motivation  |      |
|                          | and Knowledge   |      |
|                          | by Reinforcing the  |      |
|                          | Importance of Adherence   | 100  |
| 6 5 3                    | and Persistence   | 102  |
| 6.5.2                    | Provide Literature to Read  | 100  |
| 6.5.3                    | at Home<br>Write Down All Drop                                    | 102  |
| 0.5.5                    | Directions; Consider  |      |
|                          | an Easy-to-Read Chart   | 102  |
| 6.5.4                    | Regularly Evaluate  | 102  |
| 0.5.4                    | the Treatment Regimen   | 102  |
| 6.5.5                    | Improve Patient Skills  | 102  |
| 01010                    | by Monitoring Drop  |      |
|                          | Instillation Techniques   | 102  |
| 6.5.6                    | Question Patients   |      |
|                          | Concerning Adherence  |      |
|                          | and Persistence   | 102  |
| 6.5.7                    | Help Patients Fit   |      |
|                          | the Treatment Regimen   |      |
|                          | Into Their Routines   | 102  |
| 6.5.8                    | Consider Health System  |      |
|                          | lssues  | 103  |
| 6.6                      | Conclusion  | 103  |
|                          | References  | 103  |

#### **Epidemiology and Related Fields**

#### Chapter 7 Glaucoma Care in Developing Countries of Asia

Paul J. Foster and Ravi Thomas

| 7.1   | The Problem              | 110 |
|-------|--------------------------|-----|
| 7.2   | Primary Open-Angle       |     |
|       | Glaucoma                 | 110 |
| 7.3   | Primary Angle-Closure    |     |
|       | Glaucoma                 | 110 |
| 7.3.1 | Defining Primary Angle-  |     |
|       | Closure Glaucoma         | 110 |
| 7.3.2 | Incidence of Primary     |     |
|       | Angle Closure            | 112 |
| 7.3.3 | Prevalence of Primary    |     |
|       | Angle Closure            | 112 |
| 7.3.4 | Risk Factors             | 113 |
| 7.4   | Impact of Glaucoma       |     |
|       | on Patients and Access   |     |
|       | to Care                  | 114 |
| 7.5   | Medical Therapy          | 114 |
| 7.6   | Laser Treatment          | 115 |
| 7.7   | Surgery                  | 116 |
| 7.8   | Political Considerations | 117 |
| 7.9   | The Pharmaceutical       |     |
|       | Industry                 | 117 |
| 7.10  | Conclusion               | 118 |
|       | References               | 119 |
|       |                          |     |

#### Chapter 8 Health Economics, Cost-Effectiveness, and Glaucoma Care

Anja Tuulonen and Harri Sintonen

| 8.1   | Health Economics         | 123 |
|-------|--------------------------|-----|
| 8.1.1 | Basics                   | 123 |
| 8.1.2 | Role of Micro-Economic   |     |
|       | Evaluation               | 125 |
| 8.2   | Efficacy, Effectiveness, |     |
|       | and Efficiency           | 125 |
| 8.2.1 | Methods of Economic      |     |
|       | Evaluation               | 125 |
| 8.2.2 | Guidelines for Economic  |     |
|       | Evaluation               | 127 |
| 8.3   | Economic Evaluation      |     |
|       | and Glaucoma Care        | 128 |
|       |                          |     |

| 8.3.1 | Cost-Effectiveness          |     |
|-------|-----------------------------|-----|
|       | Analyses of Screening       |     |
|       | for Glaucoma                | 129 |
| 8.3.2 | Pharmacoeconomic Studies    |     |
|       | in Glaucoma                 | 129 |
| 8.3.3 | Other Cost Studies          |     |
|       | in Glaucoma                 | 130 |
| 8.4   | Future                      | 130 |
| 8.4.1 | Future Challenges in Health |     |
|       | Economics                   | 130 |
| 8.4.2 | What Kind of Information    |     |
|       | Do We Need About            |     |
|       | Glaucoma Care?              | 131 |
|       | References                  | 132 |
|       |                             |     |

#### Therapy – Surgery

#### Chapter 9

## Future of IOP-Lowering Medication for Glaucoma Therapy

Paul L. Kaufman and B'Ann True Gabelt

| 9.1   | Introduction            | 138 |
|-------|-------------------------|-----|
| 9.2   | Outflow Enhancement     | 138 |
| 9.2.1 | Trabecular Outflow      | 138 |
| 9.2.2 | Uveoscleral Outflow     | 146 |
| 9.3   | Inflow Suppression      | 148 |
| 9.3.1 | Basic Structure         | 149 |
| 9.3.2 | Opioids                 | 149 |
| 9.3.3 | Cannabinoids            | 150 |
| 9.4   | Drug Delivery           | 150 |
| 9.4.1 | Vesicular Drug Delivery | 150 |
| 9.4.2 | Contact Lenses          | 151 |
| 9.4.3 | Penetration Enhancers   | 152 |
| 9.4.4 | Bioadhesives            | 152 |
| 9.4.5 | Ocular Inserts          | 152 |
| 9.5   | IOP Monitoring          | 153 |
| 9.5.1 | Contact Lenses          | 153 |
| 9.5.2 | Implantable Sensor      | 153 |
|       | Acknowledgements        | 153 |
|       | References              | 153 |
|       |                         |     |

#### Chapter 10 Filtering Bleb Imaging with Confocal Laser Technology (Rostock Cornea Module)

Rainer Guthoff, Günther Schlunck, Thomas Klink, Franz Grehn

| 10.1<br>10.2 | Introduction<br>Confocal In Vivo FB<br>Microscopy with the RCM/<br>HRT II Based on the Laser- | 157 |
|--------------|---|-----|
|              | Scanning Technique  | 158 |
| 10.3         | Biomicroscopic FB   | 160 |
| 10.3.1       | Analysis<br>Early Postsurgical FB   | 100 |
|              | Biomicroscopy   | 160 |
| 10.3.2       | Biomicroscopy of  |     |
|              | Functioning FB with Good  |     |
|              | or Over-Filtration  | 160 |
| 10.3.3       | Tenon's Cyst  | 160 |
| 10.3.4       | Scarring FB   | 160 |
| 10.3.5       | Standardized FB   |     |
|              | Classification and Bleb   |     |
|              | Score   | 160 |
| 10.4         | General Anatomical  |     |
|              | Considerations  | 161 |
| 10.4.1       | Normal Anatomy of the FB  |     |
|              | Relevant Region   | 161 |
| 10.4.2       | Histopathology of FB  | 161 |
| 10.5         | FB Confocal In Vivo Laser-  |     |
|              | Scanning Microscopy   | 163 |
| 10.5.1       | Normal Anatomy of the FB  |     |
|              | Relevant Region   | 164 |
| 10.5.2       | Filtering Blebs   | 165 |
| 10.5.3       | Clinical Relevance of   |     |
|              | Confocal In Vivo Laser-   |     |
|              | Scanning Microscopy in  |     |
|              | Filtering Bleb Evaluation .   | 168 |
|              | References  | 168 |

#### Miscellaneous

#### Chapter 11 Update on Tube-Shunt Procedures for Glaucoma

Jeffrey Freedman

| 11.1   | Introduction                 | 173   |
|--------|------------------------------|-------|
| 11.1.1 | Basics                       | 173   |
| 11.1.2 | Bleb Physiology              | 173   |
| 11.1.3 | Therapeutic Options Related  | ł     |
|        | to Bleb Physiology           | 174   |
| 11.2   | Indications for Implant      |       |
|        | Use                          | 175   |
| 11.2.1 | Which Implants to Use        | 175   |
| 11.2.2 | Significance of Plate Size . | 175   |
| 11.2.2 | Surgical Techniques for      | 175   |
| 11.5   | Tube-Shunt Implantation      | 177   |
| 11 2 1 |                              | 177   |
| 11.3.1 | Technique for Supra-Tenon    |       |
|        | Placement of a Single-Plate  | 1 7 7 |
|        | Molteno Implant              | 177   |
| 11.4   | The Cornea and Glaucoma      |       |
|        | Implants                     | 179   |
| 11.4.1 | Corneal Decompensation       |       |
|        | in the Presence of a Pre-    |       |
|        | existing Tube Shunt          | 179   |
| 11.4.2 | Penetrating Keratoplasty     |       |
|        | May Result in Glaucoma .     | 179   |
| 11.4.3 | Summarized Information       |       |
|        | from Publications Regarding  | J     |
|        | Success of Glaucoma          |       |
|        | Implants and Penetrating     |       |
|        | Keratoplasty                 | 180   |
| 11.5   | Neovascular Glaucoma         | 180   |
| 11.6   | Complications of Glaucoma    |       |
|        | Implants                     | 181   |
| 11.6.1 | Tube-Related Problems        | 181   |
| 11.6.2 | Plate-Related Problems       | 181   |
| 11.6.3 | Motility Problems            | 182   |
| 11.6.4 | The "Hypertensive Phase"     | 182   |
| 11.6.5 | Bleb Fibrosis                | 182   |
| 11.7   | New Glaucoma Implants .      | 183   |
| 11.7.1 | The Ex-Press Glaucoma        | 105   |
| 11./.1 | Shunt                        | 183   |
| 11.8   | The Future for Glaucoma      | 105   |
| 11.0   | Implants                     | 183   |
|        | References                   | 183   |
|        |                              | 105   |
|        |                              |       |

**Subject Index** ..... 187

## Contributors

#### Michael Bach, Prof. Dr.

Universitäts-Augenklinik Freiburg Killianstraße 5 79106 Freiburg Germany

#### Andreas G. Böhm, Priv.-Doz. Dr.

Augenklinik der Technischen Universität Fetscherstraße 74 01307 Dresden Germany

#### Paul Foster, MD

Institute of Ophthalmology Bath Street London EC1 V 9EL UK

#### Jeffrey Freedman, MD, PhD

Department of Ophthalmology SUNY Downstate Medical Center 450 Clarkson Avenue, Brooklyn NY 11203 USA

#### B'Ann True Gabelt, Associate Scientist

Department of Ophthalmology and Visual Sciences University of Wisconsin 600 Highland Avenue Madison, WI 53792-3284 USA

#### Franz Grehn, Prof. Dr. Dr. h.c.

Universitäts-Augenklinik Würzburg Josef-Schneider-Straße 11 97080 Würzburg Germany

#### Rainer Guthoff, Dr.

Universitäts-Augenklinik Würzburg Josef-Schneider-Straße 11 97080 Würzburg Germany

#### Murray A. Johnstone, MD

Swedish Medical Center Department of Ophthalmology 1221 Madison #1124 Seattle, WA 98104 USA

#### Hartmut E. Kanngiesser, Dr.

Manager R&D SMT Swiss Mictrotechnology AG Allmendstrasse 11 2562 Port Switzerland

#### Paul Kaufman, MD, PhD

Professor and Chairman Department of Ophthalmology University of Wisconsin 600 Highland Avenue Madison, WI 53792-3284 USA

#### Thomas Klink, Dr.

Universitäts-Augenklinik Würzburg Josef-Schneider-Straße 11 97080 Würzburg Germany

#### Christoph Kniestedt, Dr.

Kantonsspital Winterthur Augenklinik Brauerstrasse 15, 8401 Winterthur Switzerland

#### XVI Contributors

#### Markus Kohlhaas, Prof. Dr.

St. Johannes-Hospital Johannesstraße 9–17 44137 Dortmund Germany

#### Steven Mansberger, MD

Devers Eye Institute 1040 NW 22nd Avenue #200 Portland, OR 97210 USA

#### Thomas Meigen, Priv.-Doz. Dr.

Universitäts-Augenklinik Würzburg Josef-Schneider-Straße 11 97080 Würzburg Germany

#### Emily L. Patterson, MD

Devers Eye Institute 1040 NW 22nd Avenue #200 Portland, OR 97210 USA

#### Lutz E. Pillunat, Prof. Dr.

Augenklinik der Technischen Universität Fetscherstraße 74 01307 Dresden Germany

#### Günther Schlunck, Dr.

Universitäts-Augenklinik Würzburg Josef-Schneider-Straße 11 97080 Würzburg Germany

#### Evelin Schneider, Dr.

Universitäts-Augenklinik Würzburg Josef-Schneider-Straße 11 97080 Würzburg Germany

#### Gail F. Schwartz, MD

Glaucoma Consultants 6565 N. Charles Street, Suite 302 Baltimore, MD 21204 USA

#### Harri Sintonen, PhD

Department of Public Health University of Helsinki and FinOHTA P.O. Box 41 00014 University of Helsinki Finland

#### Eberhard Spörl, Dr.

Augenklinik der Technischen Universität Fetscherstraße 74 01307 Dresden Germany

#### **Robert Stamper, MD**

Professor and Chairman Department of Ophthalmology UCSF 10 Kirkham Street, Rm K301 San Francisco, CA 94143 USA

#### **Ravi Thomas, MD**

Professor and Chairman LV Prasad Eye Institute Banjara Hills Hyderabad Andhra Pradesh India

#### Anja Tuulonen, MD

Department of Ophthalmology P.O. Box 5000 University of Oulu FIN-90014 Oulu Finland

## **Basics and Diagnosis**

#### **Chapter 1**

A New Model Describes an Aqueous Outflow Pump and Explores Causes of Pump Failure in Glaucoma

Murray A. Johnstone

#### Core Messages

- The aqueous outflow system is structurally organized to act as a mechanical pump. The aqueous outflow system is part of a vascular circulatory loop. All other vascular circulatory loops return fluids to the heart by pumping mechanisms.
- The trabecular meshwork actively distends and recoils in response to IOP transients such as the ocular pulse, blinking, and eye movement. Trabecular meshwork flexibility is essential to normal function.
- Aqueous valves transfer aqueous from the anterior chamber to SC. The valves are oriented circumferentially in SC and their normal function requires that trabecular tissues retain their ability to recoil from SC external wall.
- The aqueous pump provides short-term pressure control by varying stroke volume in response to pressure changes.

- The aqueous pump provides long-term pressure control by modulating trabecular meshwork constituents that control stroke volume.
- The aqueous outflow pump fails in glaucoma because of SC wall apposition and trabecular tissue stiffening. The trabecular meshwork (TM) stiffening is progressive and becomes irreversible.
- Clinically visible manifestations of pump failure are lack of pulsatile aqueous discharge into the aqueous veins and gradual failure in the ability to reflux blood into SC.
- Reversal of pump failure requires Schlemm's canal lumen enlargement. Precisely targeted surgical techniques directed at the scleral spur and its ciliary body attachment should reverse the structural abnormality without damaging the pump.

#### 1.1 Introduction

#### 1.1.1 Overview

Primary open-angle glaucoma is an enigma involving abnormal aqueous outflow. Constructing a model that explains normal control of pressure and flow is necessary before the enigma can be resolved. Laboratory studies describe an aqueous outflow system with properties that enable it to act as a pump. A recently proposed model describes such a pump that controls both pressure and flow [34]. This chapter summarizes confirmatory evidence that supports the pump model. It further explores how malfunction of mechanisms central to the model can explain laboratory and clinical abnormalities found in glaucoma. The ability to predict and explain laboratory and

The initial reports by both Ascher [2] and Goldmann [16] of the presence of aqueous veins point out that a mechanism is present to transmit the intraocular pulse across the trabecular meshwork to Schlemm's canal (SC) and the aqueous veins. Goldmann, Ascher, and others provide exquisitely detailed descriptions of the effect of the pumping mechanism that moves aqueous from SC into the episcleral veins [4]. It is best to start with a brief overview of the pumping mechanism model. Flexible trabecular tissue movement pumps aqueous from the anterior chamber to SC through a series of valves spanning SC (Figs. 1.1, 1.2). Trabecular tissue movement then pumps aqueous from SC to the aqueous veins. The aqueous outflow pump receives its power from transient IOP increases such as during systole of the cardiac cycle, respiration, blinking, and eye movement. These IOP transients cause deformation of the elastic structural elements of the trabecular tissues (Fig. 1.3). During systole, the pressure increase moves the trabecular tissues outward, toward SC and eventually into it (Fig. 1.4A,B). Outward movement of the Schlemm's canal endothelium (SCE) narrows SC, forcing aqueous from SC into collector channel ostia and then into the aqueous veins. Concurrently, the transient IOP increase forces aqueous from the trabecular meshwork interstices into one-way collector vessels or valves spanning SC. Decay of the pressure spike causes the elastic trabecular elements to respond by recoiling to their diastolic configuration. Trabecular tissue recoil causes a pressure reduction in SC that induces aqueous to flow from the aqueous collector vessels or valves into SC.

Stroke volume is responsible for the amount of aqueous discharged from SC with each IOP transient, thus providing short-term IOP homeostasis. The stroke volume moves up or down an IOP-dependent length-tension curve. Optimization of the stroke volume setpoint is a function of the trabecular tissue properties that determine distention and recoil. Trabecular endothelial cells regulate trabecular tissue properties. Trabecular endothelial cells act as sensors constantly monitoring information related to pressure and flow. Using the information, the endothelial cells employ mechanotransduction mechanisms to optimize their own properties as well as the constituent properties of the formed extracellular elements.

In this model, the pump controls flow and pressure; the problem of glaucoma is explained by a failure of pump function. Pump failure results from abnormally diminished trabecular tissue movement (Fig. 1.4C). Reduced trabecular tissue movement in turn results from two related abnormalities. The first abnormality is intrinsic trabecular tissue stiffening; the second is abnormal persistence of trabecular tissue apposition to SC external wall. Persistent trabecular tissue apposition develops because of both intrinsic excess distention of trabecular tissues and extrinsic factors. Extrinsic factors alter the position of trabecular tissue attachments to the scleral spur, Schwalbe's line, and ciliary body. Alterations in corneoscleral relationships, corneoscleral flexibility, and changes in ciliary body tone are examples of extrinsic factors that move the trabecular insertion within the eye. Laboratory and clinical evidence follows which provides confirmatory evidence to support the model.

#### 1.1.2 The Trabecular Meshwork Is the Wall of a Vessel


Ashton's anatomic studies [5, 6] demonstrate that SC is the wall of a vascular sinus that communicates directly with the venous system; thus, the trabecular side of SC is the highly modified wall of a vessel. When we couple Ashton's observations with those of Ascher [4] and Goldmann [16], it becomes apparent that the aqueous outflow system functions in the broader sense as one of the vascular circulatory loops returning fluids that originated from the blood (blood derived) to the heart.

#### 1.1.3 The Aqueous Outflow System Is Part of a Vascular Circulatory Loop

The cardiac pulse pumps blood to the ciliary processes. Ciliary-process epithelia then convert aqueous constituents of the blood into aque-

4

5








Fig. 1.1 Aqueous outflow anatomy when IOP is normal or decreased. *TM* trabecular meshwork, *SCE* 

Schlemm's canal endothelium, EW Schlemm's canal external wall, AV aqueous valve. (From [30])



**Fig. 1.2** Aqueous valve discharging aqueous into Schlemm's canal. Blood, intentionally refluxed into SC, is visible through the trabecular meshwork tissue (TM). Pulsatile movement of clear aqueous is visible in the funnel (F) and cylindrical (C) portion of the valve. Aqueous ejection to SC is apparent because of the whirling eddies of an aqueous–blood mixture (M) that develops with each systole. (Gonioscopic video courtesy of R. Stegmann)



**Fig. 1.3** Appearance of aqueous outflow system at physiologic IOP. *Arrows* depict deforming forces of pressure that act on Schlemm's canal endothelium. The IOP forces transmit through cellular processes to the trabecular lamellae. (From [32])

ous humor that flows into the anterior chamber. Aqueous flows from the anterior chamber through the trabecular meshwork into SC. From SC aqueous flows into aqueous veins and episcleral veins completing the closed circulatory loop that returns aqueous to the heart.

#### 1.1.4 Circulatory Loops Return Fluid to the Heart by Pumping Mechanisms

Other circulatory loops, such as the veins and lymphatics, pump fluid back to the heart by




Fig. 1.4 Trabecular meshwork (TM) movement following IOP reduction allows TM collapse, Schlemm's canal (SC) expansion, and blood reflux. A Intraocular pressure zero, episcleral venous pressure (EVP) ~8 mm Hg. The higher pressure in SC causes the highly flexible trabecular TM to collapse. The pressure on the collapsed TM forces it inward and posteriorly carrying the scleral spur (SS) and ciliary body (CB) attachment with the TM, thus greatly enlarging SC. B Intraocular pressure 25 mm Hg, EVP ~8 mm Hg. The IOP causes SC endothelium to distend outward carrying the TM with it. TM movement toward SC also forces the attached SS and CB toward SC causing closure of SC lumen. C Tissue fixation in the living eye at 25 mm Hg experimentally stiffens TM tissues. Tissue stiffening then prevents experimentally induced SC blood reflux seen in A, and simulates TM sclerosis thought to be the cause of inability to reflux blood into SC in glaucomatous eyes. Rhesus macaque. A is the fellow eye of B and C.

means of pressure transients that drive fluid in one direction through a series of valves. These valves permit pulsatile flow toward the heart in response to transients such as the cardiac pulse, respiration, muscle, and viscera movement. Vascular tissue composition determines the properties that optimize flow and pressure relationships in other vascular circulatory loops [27]. The currently proposed model uses the same physiologic principles to explain mechanisms that optimize pressure and flow relationships in the aqueous circulatory loop.

#### Summary for the Clinician

- Since the trabecular meshwork is the wall of a vessel, we can expect it to have anatomic features and physiologic behavior analogous to vessels elsewhere.
- Examination of vascular system behavior points to pumping mechanisms as a means of returning fluids to the heart.

#### 1.2 Laboratory Evidence of a Mechanical Aqueous Outflow Pump

1.2.1 Anatomic Relationships That Permit Pulsatile Flow

#### 1.2.1.1 SC Pressure Gradients Are in the "Wrong Direction" Requiring Adaptations

Although Schlemm's canal is the modified wall of a vessel, in other vessels pressure levels are higher in the vessel lumen than in the tissues around them. By contrast, pressure is higher in the tissue outside SC lumen than it is on the inside. Fluid also moves into rather than out of SC lumen. Pressure gradient and flow reversals require a unique series of adaptations of the trabecular wall of SC. The adaptations provide a means of resisting the pressure gradients that would otherwise force SC endothelium away from the trabecular lamellae and toward Schlemm's canal.

1

6

#### 1.2 Laboratory Evidence of a Mechanical Aqueous Outflow Pump

#### 1.2.1.2 Trabecular Tissue Attachment Mechanisms Provide a "Right Direction"

At the heart of the current model is a system of cellular attachments that integrate the trabecular tissues into a functional unit (Fig. 1.3) [31]. Pressure does not force SC endothelium against a basement membrane to provide intimate contact as in other vessels. The SC inner wall endothelium has only a sparse - and in some areas an absent - basement membrane; instead, in place of a basement membrane, numerous cytoplasmic processes of Schlemm's canal endothelial cells project into the juxtacanalicular space. Cytoplasmic processes of SC endothelium attach to processes projecting from juxtacanalicular cells. Juxtacanalicular cells also have processes projecting toward the trabecular lamellae. Endothelial cells covering the trabecular lamellae in turn have processes projecting toward and attaching to the juxtacanalicular cells' cytoplasmic processes. The result is that cellular processes of SC endothelium attach to cellular processes of endothelial cells covering trabecular lamellae.

Trabecular lamellae also attach to one another by cytoplasmic processes rather than by intertrabecular collagen beams that are infrequent and difficult to find microscopically. Endothelial cells covering the trabecular lamellae are the origin of the cytoplasmic processes. The cellular processes throughout the trabecular meshwork meet in the intertrabecular space with a complex zone of apposition involving robust desmosomes and gap junctions [23, 24].

#### 1.2.2 IOP Transients Move Trabecular Tissues to Power the Pump

#### 1.2.2.1 IOP Increases Cause Trabecular Tissue Distention

As pressure increases, the entire tissue monolayer of SC endothelium moves outward into SC (Fig. 1.4) [31, 34, 35]. At the same time individual endothelial cells throughout the monolayer change shape from a round appearance to an elongated plate-like shape. Individual cells tether to underlying processes and in the areas between tethering processes balloon outward to create the appearance of a series of undulating spherical structures along the monolayer when seen from SC lumen. The ballooning appearance of the distending endothelial cells is associated with the misnomer of "giant vacuoles."

Only tissues resisting a force undergo forceinduced deformation [27]. All studies examining IOP-induced tissue changes observe that SC endothelium is the principal tissue undergoing force-induced deformation (See [34] for complete reference list). All these studies thus point to the Schlemm's canal endothelial monolayer as the site of resistance to aqueous flow within the trabecular meshwork.

#### 1.2.2.2 SC Endothelium Tethering to Trabecular Lamellae Limits Movement

The following observations demonstrate that the trabecular lamellae limit SC endothelium outward movement by means of restraining tension exerted through cell processes (Fig. 1.3) [31, 35]. At cell process origins of SC endothelium, the cytoplasm and nucleus of the cells reorganize from a flat to an elongated cone-shaped configuration. Juxtacanalicular cell cytoplasmic process origins also change from a round- to a cone-shaped appearance. Cytoplasmic processes throughout the meshwork undergo progressive changes from an orientation parallel to trabecular beams to a perpendicular orientation. At the same time, the cytoplasmic processes change from a short, stubby appearance to an elongated and thin configuration. As SC endothelium stretches and moves outward into SC, the juxtacanalicular space enlarges. As IOP increases further, the trabecular lamellae stretch progressively outward toward SC lumen increasing the space between adjacent lamellae.